Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
Clin J Am Soc Nephrol
; 12(1): 50-59, 2017 01 06.
Article
en En
| MEDLINE
| ID: mdl-27799617
Palabras clave
Adult; Antibodies, Monoclonal, Humanized; Antigens, CD46; Atypical Hemolytic Uremic Syndrome; Child; Complement Factor H; Complement Inactivating Agents; Complement System Proteins; Follow-Up Studies; Hematologic Tests; Humans; Prospective Studies; Recurrence; Registries; Retreatment; Retrospective Studies; complement; creatinine; eculizumab; hemolytic uremic syndrome; renal dialysis
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Proteínas del Sistema Complemento
/
Anticuerpos Monoclonales Humanizados
/
Síndrome Hemolítico Urémico Atípico
Tipo de estudio:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Adult
/
Aged
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Clin J Am Soc Nephrol
Asunto de la revista:
NEFROLOGIA
Año:
2017
Tipo del documento:
Article
Pais de publicación:
Estados Unidos